Literature DB >> 2039542

The inhibition of monoamine oxidase by brofaromine.

M C Anderson1, P C Waldmeier, K F Tipton.   

Abstract

The inhibition of rat liver mitochondrial monoamine oxidase-A (MAO-A) by brofaromine was time-dependent at low enzyme and inhibitor concentrations. The apparent sensitivity to inhibition decreased when the concentration of the mitochondrial preparation was increased. After preincubation of the enzyme with brofaromine repeated washing of the preparation, by sedimentation and resuspension, resulted in a gradual recovery of activity. This occurred more slowly than was the case when the reversible inhibitor amphetamine was used. After incubation with radioactively-labeled brofaromine the loss of radioactivity also occurred slowly. After incubation with radioactively-labeled pargyline polyacrylamide-gel electrophoresis in the presence of sodium dodecyl sulphage (SDS-PAGE) showed the radioactivity to be associated with a peptide of approximate Mr 50,000, corresponding to the subunit of MAO. Pretreatment with unlabeled pargyline depressed this labeling by pargyline, indicating the latter compound to bind to the active-site of the enzyme. Labeling experiments with radioactive brofaromine indicated that there was a high degree of non-specific binding but that no significant radioactivity remained associated with the enzyme on SDS-PAGE. Chromatographic techniques and determination of H2O2 liberation indicated that, in liver there was no appreciable metabolism of brofaromine under the conditions used in the inhibition experiments. These data indicate brofaromine to be a tight-binding, but reversible inhibitor of MAO.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039542     DOI: 10.1016/0006-2952(91)90126-p

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Drug treatment of depression in the 1990s. An overview of achievements and future possibilities.

Authors:  H J Möller; H P Volz
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

2.  Effect of some pyrimidine compounds on rat brain monoamine oxidase-B in vitro.

Authors:  Nadia Z Shaban; Mamdouh S Masoud; Mai A Mawlawi; Doaa Awad; Omayma M Sadek
Journal:  J Physiol Biochem       Date:  2012-03-31       Impact factor: 4.158

Review 3.  Brofaromine--a review of its pharmacological properties and therapeutic use.

Authors:  H P Volz; C H Gleiter; P C Waldmeier; M Struck; H J Möller
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Pirlindole and dehydropirlindole protect rat cultured neuronal cells against oxidative stress-induced cell death through a mechanism unrelated to MAO-A inhibition.

Authors:  A Boland; J Gérardy; D Mossay; D Delapierre; V Seutin
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

5.  Effects of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase-A and on GABAA receptors.

Authors:  A E Medvedev; V I Shvedov; T M Chulkova; O A Fedotova; E Saederup; R F Squires
Journal:  Neurochem Res       Date:  1996-12       Impact factor: 3.996

6.  In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.

Authors:  N Bel; F Artigas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

7.  Monoamine oxidase inhibitors and the cheese effect.

Authors:  M C Anderson; F Hasan; J M McCrodden; K F Tipton
Journal:  Neurochem Res       Date:  1993-11       Impact factor: 3.996

Review 8.  Catching a glimpse of the bacterial gut community of companion animals: a canine and feline perspective.

Authors:  Giulia Alessandri; Chiara Argentini; Christian Milani; Francesca Turroni; Maria Cristina Ossiprandi; Douwe van Sinderen; Marco Ventura
Journal:  Microb Biotechnol       Date:  2020-08-30       Impact factor: 5.813

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.